SunTrust Banks reissued their buy rating on shares of Stryker (NYSE:SYK) in a report released on Friday, January 26th, MarketBeat reports. The firm currently has a $179.00 target price on the medical technology company’s stock, up from their previous target price of $161.00.
A number of other analysts also recently issued reports on SYK. Royal Bank of Canada reaffirmed a buy rating and issued a $155.00 target price on shares of Stryker in a research note on Monday, October 2nd. Cowen set a $160.00 price objective on Stryker and gave the stock a buy rating in a research report on Friday, October 6th. Zacks Investment Research downgraded Stryker from a hold rating to a sell rating in a research report on Monday, October 16th. Robert W. Baird reaffirmed a hold rating and issued a $161.00 target price on shares of Stryker in a research report on Friday, October 27th. Finally, Piper Jaffray Companies reaffirmed a buy rating and issued a $156.00 target price on shares of Stryker in a research report on Friday, October 27th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and fourteen have given a buy rating to the stock. The company currently has a consensus rating of Hold and an average price target of $162.50.
Stryker (NYSE:SYK) opened at $153.66 on Friday. Stryker has a fifty-two week low of $122.78 and a fifty-two week high of $170.00. The company has a current ratio of 2.29, a quick ratio of 1.59 and a debt-to-equity ratio of 0.66. The stock has a market cap of $57,510.00, a PE ratio of 57.34, a PEG ratio of 2.17 and a beta of 0.70.
Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $1.96 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.95 by $0.01. The company had revenue of $3.47 billion for the quarter, compared to the consensus estimate of $3.42 billion. Stryker had a net margin of 8.20% and a return on equity of 24.56%. Stryker’s quarterly revenue was up 9.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.78 EPS. sell-side analysts forecast that Stryker will post 7.12 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Monday, April 30th. Stockholders of record on Thursday, March 29th will be issued a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 1.22%. The ex-dividend date of this dividend is Wednesday, March 28th. Stryker’s payout ratio is currently 70.15%.
In other Stryker news, Director Howard E. Cox, Jr. sold 7,400 shares of the business’s stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $164.09, for a total transaction of $1,214,266.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP William E. Berry, Jr. sold 1,306 shares of the business’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $164.42, for a total value of $214,732.52. The disclosure for this sale can be found here. Insiders have sold 16,840 shares of company stock worth $2,749,989 in the last ninety days. 7.40% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SYK. Beach Investment Management LLC. acquired a new stake in Stryker during the second quarter worth about $1,924,000. Synovus Financial Corp grew its stake in shares of Stryker by 4.6% in the second quarter. Synovus Financial Corp now owns 3,997 shares of the medical technology company’s stock valued at $553,000 after buying an additional 174 shares in the last quarter. Intercontinental Wealth Advisors LLC acquired a new stake in shares of Stryker in the second quarter valued at about $347,000. Meiji Yasuda Life Insurance Co acquired a new stake in shares of Stryker in the second quarter valued at about $402,000. Finally, Armor Investment Advisors LLC grew its stake in shares of Stryker by 1.0% in the second quarter. Armor Investment Advisors LLC now owns 5,000 shares of the medical technology company’s stock valued at $694,000 after buying an additional 50 shares in the last quarter. Hedge funds and other institutional investors own 74.71% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/13/strykers-syk-buy-rating-reiterated-at-suntrust-banks.html.
Stryker Company Profile
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.